Neil Fleshner

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. pmc Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4
    David Cervi
    1Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    BMC Cancer 10:258. 2010
  2. ncbi request reprint Should finasteride be used to prevent prostate cancer?
    Neil Fleshner
    University Health Network, 610 University Avenue, 3 130, Toronto, Ontario, M5G 2M9, Canada
    Curr Treat Options Oncol 7:346-54. 2006
  3. doi request reprint Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium
    Neil E Fleshner
    University Health Network, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario Canada
    J Clin Oncol 29:2386-90. 2011
  4. ncbi request reprint Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial
    Neil Fleshner
    University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    Contemp Clin Trials 28:763-9. 2007
  5. doi request reprint Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer
    Alfonso Gómez-Iturriaga Piña
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urology 75:1412-6. 2010
  6. doi request reprint A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies
    Stephane Supiot
    Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Radiother Oncol 88:53-60. 2008
  7. ncbi request reprint Perineural invasion on prostate biopsy does not predict adverse pathological outcome
    Malik Elharram
    University of Toronto, Toronto, Ontario, Canada
    Can J Urol 19:6567-72. 2012
  8. doi request reprint Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors
    Dean Sol Elterman
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 183:2085-9. 2010
  9. doi request reprint 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging
    Nathan Lawrentschuk
    University of Toronto, ON, Canada
    BJU Int 105:1231-6. 2010
  10. doi request reprint Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Urol 187:1247-52. 2012

Detail Information

Publications85

  1. pmc Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4
    David Cervi
    1Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada
    BMC Cancer 10:258. 2010
    ..The purpose herein was to discover, validate and characterize functional biomarkers of dietary supplementation capable of suppressing the course of prostate cancer in vivo...
  2. ncbi request reprint Should finasteride be used to prevent prostate cancer?
    Neil Fleshner
    University Health Network, 610 University Avenue, 3 130, Toronto, Ontario, M5G 2M9, Canada
    Curr Treat Options Oncol 7:346-54. 2006
    ..Additional trials of antiestrogens, micronutrients, and other 5ARIs, which will mature over the next 2 to 5 years, will better define the role of 5ARIs in prostate cancer chemoprevention...
  3. doi request reprint Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium
    Neil E Fleshner
    University Health Network, Princess Margaret Hospital, 610 University Ave, Toronto, Ontario Canada
    J Clin Oncol 29:2386-90. 2011
    ..This hypothesis was tested in a randomized phase III double-blind study of daily soy (40 g), vitamin E (800 U), and selenium (200 μg) versus placebo...
  4. ncbi request reprint Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial
    Neil Fleshner
    University Health Network, Princess Margaret Hospital, Toronto, ON, Canada
    Contemp Clin Trials 28:763-9. 2007
    ..Dutasteride, a dual 5alpha-reductase inhibitor (5ARI), may delay prostate cancer progression or extend the time to initiation of more aggressive therapy...
  5. doi request reprint Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer
    Alfonso Gómez-Iturriaga Piña
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urology 75:1412-6. 2010
    ..To report the genitourinary (GU) and gastrointestinal (GI) toxicity rates, erectile function preservation, and biochemical outcome (bNED) in men aged<or=55 years treated with 125iodine (125I) brachytherapy (BT)...
  6. doi request reprint A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies
    Stephane Supiot
    Princess Margaret Hospital University Health Network, Toronto, Ont, Canada
    Radiother Oncol 88:53-60. 2008
    ..In a phase I trial, we investigated the feasibility of pre-operative radiotherapy for this patient subset...
  7. ncbi request reprint Perineural invasion on prostate biopsy does not predict adverse pathological outcome
    Malik Elharram
    University of Toronto, Toronto, Ontario, Canada
    Can J Urol 19:6567-72. 2012
    ..The aim of this present study is to determine the role of PNI on prostate biopsy in predicting adverse findings at radical prostatectomy in a recent cohort of screen detected prostate cancer...
  8. doi request reprint Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors
    Dean Sol Elterman
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 183:2085-9. 2010
    ..Thus, we determined whether pharmacological doses of alpha-blockers and/or 5alpha-reductase inhibitors were present in a sample of phytotherapeutic agents for benign prostatic hyperplasia...
  9. doi request reprint 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging
    Nathan Lawrentschuk
    University of Toronto, ON, Canada
    BJU Int 105:1231-6. 2010
    ....
  10. doi request reprint Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Urol 187:1247-52. 2012
    ..We report magnetic resonance imaging findings among unselected men with low risk prostate cancer before active surveillance...
  11. doi request reprint Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies
    Jocelyn Stewart
    Department of Pathology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
    J Urol 179:1751-5; discussion 1755. 2008
    ..This study evaluates the prognostic significance of alpha-methylacyl-coA racemase positive high grade prostatic intraepithelial neoplasia glands in prostate biopsies...
  12. doi request reprint Association between metformin use and risk of prostate cancer and its grade
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    J Natl Cancer Inst 105:1123-31. 2013
    ..Recent evidence suggests that it may possess antitumoral properties. The aim of this study was to test the association between metformin use and risk of prostate cancer and its grade among men with diabetes...
  13. doi request reprint Prevalence and predictors of selenium and vitamin E supplementation in a urology population
    Jennifer Locke
    Urology Program, Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada
    J Altern Complement Med 19:128-33. 2013
    ....
  14. pmc Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
    Paul Toren
    Division of Urology, Department of Surgery, University of Toronto, University Health Network, 610 University Avenue, 3 130, Toronto, Ontario, Canada M5G 2M9
    BMJ 346:f2109. 2013
    ..To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates...
  15. doi request reprint Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer
    Ken Kron
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 18:2896-904. 2012
    ..The aim of this study was to analyze the relationship between ERG expression, DNA methylation of three biomarkers, and clinicopathologic features of prostate cancer...
  16. doi request reprint Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection
    Abdullah M Al-Ghamdi
    University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 179:1332-4. 2008
    ..A basic tenet of measurement theory is that repeat measurement improves validity. We determined whether an extended pattern prostate biopsy technique could overcome this bias...
  17. doi request reprint The role of 5-alpha-reductase inhibitors in active surveillance
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Curr Opin Urol 22:243-6. 2012
    ..In this context, we will present recent data on the efficacy of 5-alpha-reductase inhibitors (5-ARIs) in secondary prevention among men with low-risk PCa choosing active surveillance...
  18. doi request reprint Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma
    Robert Abouassaly
    Division of Urologic Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Urology 76:895-901. 2010
    ..Complete nephroureterectomy is the standard of care, and increasing evidence has shown that a suboptimal surgical technique is associated with an adverse prognosis...
  19. doi request reprint Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy
    Antonio Finelli
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 182:2280-4. 2009
    ..We compared the incidence of small bowel within the planning target volume for radiotherapy to the prostate bed in patients who underwent open retropubic and laparoscopic radical prostatectomy...
  20. doi request reprint Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet
    Min Hou
    Division of Urology, Sunnybrook Health Science Centre, Toronto, Ontario, Canada
    Biochem Biophys Res Commun 397:537-42. 2010
    ..These effects may explain its translational role relating to its anti-neoplastic potential...
  21. doi request reprint Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer
    Shabbir M H Alibhai
    University Health Network, Toronto, Ontario, Canada
    J Clin Oncol 28:5030-7. 2010
    ..To evaluate the effects of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC)...
  22. doi request reprint Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial
    Juanita Mary Crook
    University of Toronto, University Health Network, and Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 29:362-8. 2011
    ..We report health-related quality of life (HRQOL) at a mean of 5.3 years for 168 trial-eligible men who either chose or were randomly assigned to RP or BT following a multidisciplinary educational session...
  23. doi request reprint Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologist's practice patterns
    Nathan Lawrentschuk
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, 610 University Ave 3 130, Toronto, ON, M5G 2M9, USA
    Int Urol Nephrol 43:31-7. 2011
    ..Our aim was to conduct a contemporary survey of urologist's practice patterns toward PC detection, specifically focusing on factors determining the decision to recommend ultrasound-guided biopsy (TRUS-BX)...
  24. doi request reprint Impact of positive surgical margins after radical prostatectomy differs by disease risk group
    Sultan Alkhateeb
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    J Urol 183:145-50. 2010
    ..We examined the relationship of positive surgical margins to biochemical progression according to several clinicopathological features...
  25. doi request reprint mTOR-RAPTOR and 14-3-3σ immunohistochemical expression in high grade prostatic intraepithelial neoplasia and prostatic adenocarcinomas: a tissue microarray study
    Sevan Evren
    Department of Laboratory Medicine, University Health Network, Toronto, Ontario, Canada
    J Clin Pathol 64:683-8. 2011
    ..The correlation of mTOR, RAPTOR and 14-3-3σ in high grade prostatic intraepithelial neoplasia (HGPIN) and prostate cancer has not previously been investigated...
  26. ncbi request reprint Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation
    Peter S Bunting
    Department of Clinical Pathology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Clin Biochem 35:471-5. 2002
    ..To determine the intraindividual variation of prostate-specific antigen (PSA) isoforms in prostate cancer patients managed conservatively with watchful observation...
  27. doi request reprint Information needs of men on androgen deprivation therapy
    Tony Soeyonggo
    University of Toronto, Toronto, Canada
    BJU Int 109:1503-9. 2012
    ..A key area to enhance patient education appears to be side effects, especially around hot flashes and fatigue, which were also the most bothersome treatment sequelae for patients...
  28. doi request reprint External validation of a biomarker based pre-cystectomy algorithm to predict nonorgan confined urothelial cancers
    David Margel
    Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Urol 187:840-4. 2012
    ..This algorithm included tumor markers (CEA, CA 125 and CA 19-9) as well as clinical parameters. In this study we validated the accuracy of this algorithm in an independent, external cohort...
  29. ncbi request reprint Rethinking 30-day mortality risk after radical prostatectomy
    Shabbir M H Alibhai
    Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Ontario, Canada
    Urology 68:1057-60. 2006
    ..Although radical prostatectomy (RP) is associated with greater 30-day mortality in older men, the magnitude of the excess risk in older age groups compared with younger ones has not been well characterized...
  30. pmc Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study
    Jocelyn Stewart
    Department of Pathology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada
    J Clin Pathol 60:773-80. 2007
    ..Current ancillary markers for diagnosis in prostate biopsies include p63 and alpha-methylacyl-CoA racemase (AMACR). Annexin II (ANXII), a calcium and phospholipid binding protein, is lost in prostate cancer...
  31. ncbi request reprint Variation in patterns of practice in diagnosing screen-detected prostate cancer
    Robert K Nam
    Division of Urology, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Canada
    BJU Int 94:1239-44. 2004
    ....
  32. doi request reprint The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels
    Nathan Lawrentschuk
    Division of Urology, University Health Network, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    BJU Int 103:730-3. 2009
    ..A comparison study and cost-benefit analysis of MRI-targeted vs saturation biopsy in this group of patients would also be ideal, to delineate any advantages...
  33. doi request reprint Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes
    David Margel
    Princess Margaret Hospital, University Health, Toronto, Canada
    J Clin Oncol 31:3069-75. 2013
    ..To evaluate the association between cumulative duration of metformin use after prostate cancer (PC) diagnosis and all-cause and PC-specific mortality among patients with diabetes...
  34. ncbi request reprint Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL
    Rami Al-Azab
    Division of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
    Urology 69:103-7. 2007
    ..0 and 9.0 ng/mL. If this hypothesis were correct, within these ranges, a smaller prostate volume would be a stronger predictor of cancer than the PSA level itself (the relative contribution from cancer is greater in smaller glands)...
  35. doi request reprint Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer
    Ken Kron
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Clin Cancer Res 19:3450-61. 2013
    ....
  36. ncbi request reprint Defining high-risk prostate cancer: current status
    Neil Fleshner
    Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 12:14-7; discussion 94-6. 2005
    ..Softer risk factors such as obesity, race, socioeconomic status, and genetic polymorphisms are increasingly being studied. Ultimately high-throughput genomics will aid in identification of these men...
  37. ncbi request reprint Management of low-stage testicular seminoma
    Mischel Neill
    Division of Urology, Department of Surgery, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Canada
    Urol Clin North Am 34:127-36; abstract vii-viii. 2007
    ..Radiation therapy remains the mainstay of therapy for patients who have stage IIa disease...
  38. pmc A whole-genome SNP association study of NCI60 cell line panel indicates a role of Ca2+ signaling in selenium resistance
    Sevtap Savas
    Fred A Litwin Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    PLoS ONE 5:e12601. 2010
    ....
  39. doi request reprint Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells
    Ahmed Q Haddad
    Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Nutr Cancer 62:668-81. 2010
    ..Other functional categories altered included chromosome organization, apoptosis, and stress response. These results demonstrate the multiple mechanisms of antitumor activity of DHC and fisetin in prostate cancer cells in vitro...
  40. doi request reprint Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men
    Alexandre R Zlotta
    Department of Surgery, Division of Urology, University of Toronto, Mount Sinai Hospital, Toronto, ON, M5T 3L9, Canada
    J Natl Cancer Inst 105:1050-8. 2013
    ..We prospectively compared PCa prevalence in CAU and ASI men from specific populations with low penetrance of prostate-specific antigen screening...
  41. doi request reprint Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients
    Dennis Wagner
    Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada
    J Clin Endocrinol Metab 98:1498-507. 2013
    ..Vitamin D3 might benefit prostate cancer (PCa) patients because prostate cells can locally synthesize the active hormone calcitriol...
  42. doi request reprint Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence
    Nathan Lawrentschuk
    University of Toronto, University Health Network, Department of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 185:848-54. 2011
    ..Secondary objectives were to calculate the PSA response and determine whether sequence order impacted the response...
  43. doi request reprint Immunohistochemical examination of the mTORC1 pathway in high grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinomas (PCa): a tissue microarray study (TMA)
    Sevan Evren
    Department of Laboratory Medicine, University Health Network, Toronto, ON, Canada
    Prostate 70:1429-36. 2010
    ..Upregulation of this pathway can lead to an aberrant increase in cell growth and metabolism characteristic of malignant transformation...
  44. doi request reprint Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer
    David Margel
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Urology 78:848-54. 2011
    ..Given that immune response is attenuated with age, we set out to determine the impact of age on response to BCG...
  45. doi request reprint Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer
    Abbas H Panju
    Department of Medicine, University Health Network, Toronto, Ontario, Canada
    BJU Int 103:753-7. 2009
    ....
  46. ncbi request reprint Does prolonging the time to renal cancer surgery affect long-term cancer control: a systematic review of the literature
    Michael Jewett
    University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    Can J Urol 13:54-61. 2006
    ..e., recurrence-free survival, overall survival)?..
  47. ncbi request reprint Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial
    Kris Wallace
    Department of Radiation Medicine and the Division of Urology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    J Clin Oncol 24:4158-62. 2006
    ..A multidisciplinary educational session was developed to improve patient understanding of treatment options and to facilitate accrual...
  48. ncbi request reprint A reliable coding system to define screening prostate-specific antigen tests was developed in a case-control study
    Peter S Bunting
    Division of Biochemistry, Department of Pathology and Laboratory Medicine, University of Ottawa, Ontario, Canada
    J Clin Epidemiol 58:639-44. 2005
    ..To establish the reliability of a coding system for screening and diagnostic prostate-specific antigen (PSA) testing from patient charts...
  49. doi request reprint Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study
    David Margel
    a Division of Urology, Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada Electronic address
    J Urol 190:2039-45. 2013
    ..We identify risk factors for pathological progression among men on active surveillance in the REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management trial)...
  50. doi request reprint The effect of radiation on semen quality and fertility in men treated with brachytherapy for early stage prostate cancer
    Dilpreet K Singh
    Division of Urology, Princess Margaret Hospital and Mount Sinai Hospital, Toronto, Ontario, Canada
    J Urol 187:987-9. 2012
    ..We determined the effects of prostatic brachytherapy on semen parameters and sperm DNA integrity, and the potential impact on fertility...
  51. doi request reprint The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma
    Michael Ordon
    Department of Pathology, University Health Network, Toronto, Canada
    BJU Int 104:1641-5. 2009
    ....
  52. ncbi request reprint Surgical wait times for patients with urological cancers: a survey of Canadian surgeons
    Neil Fleshner
    University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada
    Can J Urol 13:3-13. 2006
    ..To obtain such data, a survey of Canadian urological surgeons was undertaken...
  53. ncbi request reprint Prostate cancer: chemoprevention update 2005
    Neil Fleshner
    Department of Surgery Urology, University Health Network and University of Toronto, Toronto, Ontario, Canada
    Can J Urol 12:2-4. 2005
    ..If an agent can slow the growth of existing prostate cancer cells, it remains plausible that it may be effective as an adjunct to surgery, radiation or chemotherapy...
  54. ncbi request reprint Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics
    Heather Boon
    Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
    Urology 62:849-53. 2003
    ..To ascertain the prevalence of the use of complementary/alternative medicine (CAM) among a random sample of Ontario (Canadian) men diagnosed with prostate cancer and to explore in what way users of CAM differ from nonusers...
  55. doi request reprint Most renal oncocytomas appear to grow: observations of tumor kinetics with active surveillance
    Sarah Kawaguchi
    Division of Urology, Department of Surgery, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    J Urol 186:1218-22. 2011
    ..We examined the growth of tissue proven renal oncocytoma on serial imaging to improve our understanding of its natural history...
  56. ncbi request reprint 30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity
    Shabbir M H Alibhai
    Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Canada
    J Natl Cancer Inst 97:1525-32. 2005
    ..Prior studies have suggested an increased risk of short-term complications among older men who underwent radical prostatectomy, but these studies did not adjust for comorbidity...
  57. ncbi request reprint Role of "saturation biopsy" in the detection of prostate cancer among difficult diagnostic cases
    Neil Fleshner
    Department of Urology Surgery, Toronto Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Urology 60:93-7. 2002
    ..Clinicians are commonly faced with the dilemma of elevating PSA levels despite negative prostate biopsy results in patients without symptoms of prostatitis...
  58. ncbi request reprint Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men
    David J A Jenkins
    Clinical Nutrition and Risk Factor Modification Center, St Michael s Hospital, 61 Queen St East, Toronto, Ontario, Canada M5C 2T2
    J Urol 169:507-11. 2003
    ..Soy proteins used to lower serum cholesterol are rich sources of phytoestrogens. Therefore, we assessed the effect of soy consumption on serum PSA in men who had participated in cholesterol lowering studies...
  59. ncbi request reprint Dietary fat and prostate cancer
    Neil Fleshner
    Division of Urology and Department of Surgical Oncology, Princess Margaret Hospital, University of Toronto, Canada
    J Urol 171:S19-24. 2004
    ..We provide a critical appraisal of the existing evidence for an association between dietary fat consumption and prostate cancer, and review the biologically plausible relationships...
  60. ncbi request reprint Remission of hormone-refractory prostate cancer attributed to Essiac
    Wigdan Al-Sukhni
    Division of Urology, The Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 12:2841-2. 2005
    ..We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea...
  61. ncbi request reprint Climacturia following radical prostatectomy: prevalence and risk factors
    Jason Lee
    University Health Network Princess Margaret Hospital, University of Toronto, Toronto, Ontario
    J Urol 176:2562-5; discussion 2565. 2006
    ..Following radical prostatectomy urine leakage during orgasm is a poorly defined entity. We defined the prevalence, quantity, bother and coping mechanisms associated with this complication, called climacturia...
  62. pmc Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour
    Corwyn Rowsell
    Department of Pathology and Laboratory Medicine, Toronto General Hospital, University Health Network, Toronto, Ontario, Canada
    J Clin Pathol 60:426-8. 2007
    ..The cells in the papillary tumour contained three copies, whereas the oncocytoma cells contained only two per nucleus. To our knowledge, this is the first report of a papillary RCC being identified within an oncocytoma...
  63. pmc Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays
    Ken Kron
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    PLoS ONE 4:e4830. 2009
    ..Such occurrences often lead to the silencing of these key genes and thus they may contribute to the development of cancer, including prostate cancer...
  64. doi request reprint Clinical stage I seminoma: the case for surveillance
    Nathan Lawrentschuk
    Division of Urology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    World J Urol 27:433-9. 2009
    ..This review will focus on CSI seminoma and the controversies surrounding its treatment and based upon current available evidence will outline the case for surveillance...
  65. doi request reprint A BRCA1 mutation is not associated with increased indicators of oxidative stress
    Joanne Kotsopoulos
    Women s College Research Institute, Women s College Hospital, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Ontario, Canada
    Clin Breast Cancer 8:506-10. 2008
    ..It is possible that individuals with a BRCA1 mutation might be susceptible to the effects of oxidative stress. The aim of this study was to evaluate whether women with a BRCA1 mutation exhibit increased indicators of oxidative stress...
  66. ncbi request reprint Long-term urinary sequelae following 125iodine prostate brachytherapy
    Juanita Crook
    Department of Radiation Oncology, University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Urol 179:141-5; discussion 146. 2008
    ..We describe long-term urinary function in men treated with 125iodine brachytherapy without supplemental beam irradiation...
  67. ncbi request reprint Prostate cancer prevention: past, present, and future
    Neil Fleshner
    Division of Urology, University Health Network, and Department of Surgery Urology, University of Toronto, Toronto, Ontario, Canada
    Cancer 110:1889-99. 2007
    ..Probably no cancer is being investigated more thoroughly in the context of prevention as prostate cancer in 2007. Definitive answers to pivotal phase 3 trials will be available in the coming 2 to 7 years...
  68. ncbi request reprint The experiences of men receiving androgen deprivation treatment for prostate cancer: a qualitative study
    Ross E Gray
    Psychosocial and Behavioral Research Unit, Sunnybrook and Women s Health Sciences Centre, Toronto, Ontario, Canada
    Can J Urol 12:2755-63. 2005
    ..This exploratory study was intended to investigate men's ways of integrating and understanding experiences with Androgen Deprivation Therapy (ADT), including how hormone treatment affected their sense of identity...
  69. ncbi request reprint Thirty-five years of noninvasive bladder carcinoma: a plea for the use of papillary intraurothelial neoplasia as new terminology
    Theodorus H van der Kwast
    Department of Pathology and Laboratory Medicine, University Health Network and Mount Sinai Hospital, University of Toronto, Ontario, Canada
    Anal Quant Cytol Histol 30:309-15. 2008
    ..To harmonize nomenclature, we now propose that the terms low and high grade papillary urothelial carcinoma be replaced by low and high grade papillary intraurothelial neoplasiafor all noninvasive urothelial cancers...
  70. ncbi request reprint MYH mutations are rare in prostate cancer
    Eyun Jung Shin
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    J Cancer Res Clin Oncol 133:373-8. 2007
    ..A compromised base-excision repair function due to defective MYH may contribute to prostate carcinogenesis. Here, we examine the genetic contribution of MYH to prostate cancer risk...
  71. pmc Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
    Sultan S Alkhateeb
    Department of Surgical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Canada
    Urol Ann 3:119-26. 2011
    ....
  72. ncbi request reprint Development of prostate cancer quality indicators: a modified Delphi approach
    Anna R Gagliardi
    Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario, Canada
    Can J Urol 12:2808-15. 2005
    ..Care could be improved by first identifying critical, measurable indicators that correlate with quality of care. This work was conducted to develop indicators of prostate cancer care using a modified three-step Delphi approach...
  73. ncbi request reprint Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors
    Neil Fleshner
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    J Urol 174:636-41; discussion 641; quiz 801. 2005
    ..We determined if pharmacological dosages of phosphodiesterase type 5 inhibitors (PDE5) inhibitors were present within a group of natural products marketed for the treatment of erectile dysfunction...
  74. ncbi request reprint Differences between urologists in United States and Canada in approach to bladder cancer
    Doreen Chung
    Department of Surgery, Division of Urology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Urology 65:919-25. 2005
    ..To determine the Canada-United States differences with respect to the detection, diagnosis, surveillance, and treatment of bladder cancer...
  75. pmc Does the reflexive measurement of free PSA have a role in a tertiary cancer centre?
    Christopher Allard
    University of Toronto, Toronto, ON
    Can Urol Assoc J 4:317-20. 2010
    ..We hypothesize that reflexive free PSA testing at tertiary cancer centres generates unnecessary costs as the test is often conducted on patients with previous diagnoses of prostate cancer...
  76. ncbi request reprint Treatment of the inguinal regions in penile cancer: a review of the literature and treatment proposal
    Daniel Taussky
    Department of Radiation Oncology and Surgical Oncology, Princess Margaret Hospital and the University Health Network, University of Toronto, Toronto, Ontario, Canada
    Can J Urol 13:2978-83. 2006
    ..The literature, which consists mainly of retrospective studies of patients treated over several decades, is not conclusive. We undertook a literature review to address this issue and to propose...
  77. ncbi request reprint Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression
    Richard Choo
    Toronto Sunnybrook Regional Cancer Center and Sunnybrook and Women s College Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    J Urol 167:1664-9. 2002
    ..We assessed the feasibility of a watchful waiting protocol with selective delayed intervention using clinical, prostate specific antigen (PSA) or histological progression as treatment indications for clinically localized prostate cancer...
  78. ncbi request reprint Controversies in the management of testicular seminoma
    Neil Fleshner
    Division of Urology, Department of Surgery, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Semin Urol Oncol 20:227-33. 2002
    ..The high failure rate outside the treatment field has now changed this paradigm to one of up-front chemotherapy...
  79. ncbi request reprint Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study
    Jacek A Kopec
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Urol 174:495-9; discussion 499. 2005
    ..There is limited evidence that screening is effective in reducing mortality from prostate cancer. In the current study we determined if screening with PSA reduces the risk of metastatic prostate cancer...
  80. ncbi request reprint An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer
    Armen G Aprikian
    Department of Surgery, McGill University, MUHC Montreal General Hospital, Montreal, Quebec, Canada
    Can J Urol 10:1986-94. 2003
    ..To provide context in oncology for the significance of the benefits and cost of combined androgen blockade (CAB) in the treatment of advanced prostate cancer...
  81. ncbi request reprint First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement
    Ian M Thompson
    University of Texas Health Science Center at San Antonio, Texas 78229, USA
    J Urol 171:S3-4. 2004
  82. ncbi request reprint Does prolonging the time to prostate cancer surgery impact long-term cancer control: a systematic review of the literature
    Fred Saad
    University of Montreal, CHUM, Hopital Notre Dame, Montreal, Quebec, Canada
    Can J Urol 13:16-24. 2006
    ..Is there a known association between duration of wait time beyond the recommended standard and clinical outcome (i.e. recurrence free survival, overall survival)?..
  83. pmc Radical prostatectomy as treatment for prostate cancer
    Michael A S Jewett
    Uro Oncology Program, Division of Urology, University of Toronto
    CMAJ 168:44-5. 2003
  84. ncbi request reprint An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases
    Christopher P Evans
    Department of Urology, University of California, Davis School of Medicine, 4860 Y St, Suite 3500, Sacramento, CA 95817, USA
    BJU Int 95:743-9. 2005
  85. ncbi request reprint The role of bisphosphonates in the management of bone metastases in prostate cancer
    Fred Saad
    Department of Urology, University of Montreal CHUM, Montreal, Quebec, Canada
    Can J Urol 11:2376-82. 2004
    ..This article reviews the burden of skeletal complications in patients with prostate cancer, and the evidence for the use of bisphosphonates for the treatment of skeletal morbidity in this patient population...